Track TERN and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Terns Pharmaceuticals Inc
1065 East Hillsdale Boulevard, Foster City, CA, United States, 94404
IPO
2021
Employees
59
Industry
Biotechnology
Sector
Healthcare
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. As of May 4, 2026, Terns Pharmaceuticals, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q2 20261-1
0
Q1 20265-5
0
Q4 20252-2
0
Q3 20251-1
0
Q2 20250+4
4
5-quarter cumulative
9 sells4 buys
Analyst Ratings
4 analysts covering
Buy50%recommend buy
Buy
2
Hold
2
Sell
0